When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Open accessThe DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Abstract
While Alzheimer’s disease (AD) classical diagnostic criteria rely on clinical data from a stablished symptomatic disease, newer criteria aim to identify the disease in its earlier stages. For that, they incorporated the use of AD’s specific biomarkers to reach a diagnosis, including the identification of Aβ and tau depositions, glucose hypometabolism, and cerebral atrophy. These biomarkers created a new concept of the disease, in which AD’s main pathological processes have already taken place decades before we can clinically diagnose the first symptoms. Therefore, AD is now considered a dynamic disease with a gradual progression, and dementia is its final stage. With that in mind, new models were proposed, considering the orderly increment of biomarkers and the disease as a continuum, or the variable time needed for the disease’s progression. In 2011, the National Institute on Aging and the Alzheimer’s Association (NIA-AA) created separate diagnostic recommendations for each stage of the disease continuum—preclinical, mild cognitive impairment, and dementia. However, new scientific advances have led them to create a unifying research framework in 2018 that, although not intended for clinical use as of yet, is a step toward shifting the focus from the clinical symptoms to the biological alterations and toward changing the future diagnostic and treatment possibilities. This review aims to discuss the role of biomarkers in the onset of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nonetheless, pathological changes in the brain begin during the preclinical stage, decades before clinical symptoms.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 10×
“In early AD, the first detectable signs that can be observed in a structural MRI are atrophy in the middle temporal lobe (affecting specially the hippocampus), and a decrease in the thickness of the cerebral cortex in regions that are vulnerable to AD [73–81].”
BackgroundInfluentialImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · cited 10×
“Indeed, it is included in both the Dubois [8] and the NIA-AA [16] diagnostic criteria and its specificity and sensitivity as an AD marker is greater than 85% [60].”
BackgroundMethodInfluentialInterplay between Cortical Spreading Depolarization and Seizures
Kramer, D. R., Fujii, T., Ohiorhenuan, I., & Liu, C. Y. (2017) · Stereotactic and Functional Neurosurgery · doi:10.1159/000452841 · Cited by 3,696
An Energy Budget for Signaling in the Grey Matter of the Brain
Attwell, D., & Laughlin, S. B. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200110000-00001 · Cited by 3,543 · cited 1×
“In addition, it correlates with decreased levels of synaptophysin found post-mortem that indicate a loss of synaptic activity [58,59].”
BackgroundScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Cited by
Items 101–146 of 146
Modern approaches to personalized neurology
Tanashyan, M. М. (2023) · Russian Journal for Personalized Medicine · doi:10.18705/2782-3806-2023-3-5-22-31
CUIDADOS PALIATIVOS NA DOENÇA DE ALZHEIMER: RELATO DE EXPERIÊNCIA
Moura, C. A. D., & Lopes, G. D. S. (2023) · Revista Contemporânea · doi:10.56083/rcv3n12-151
Satoh, K., Sato‐Ueshima, M., Kagami‐Katsuyama, H., Nakamura, M., Ogata, A., Maeda‐Yamamoto, M., & Nishihira, J. (2024) · Journal of Biotechnology and Biomedicine · doi:10.26502/jbb.2642-91280125
Identifying Alzheimer’s disease-associated genes using PhenoGeneRankerPreprint
Rahman, M. T., Saeed, F., Bozdag, S., & Initiative, A. D. N. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.12.623269
Pattison, M., Begde, A., & Wilcockson, T. D. W. (2025) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/smuxv_v1
Concordância interobservador do escore visual de atrofia do córtex entorrinal (ERICA)
Dutra, I. M., & Júnior, M. R. (2025) · Revista Brasileira de Pesquisa em Saúde/Brazilian Journal of Health Research · doi:10.47456/rbps.v26isupl_3.02
kumari, D., Choudhary, M., Bamrah, P. K., Malan, A., & nitesh, N. (2025) · The Natural Products Journal · doi:10.2174/0122103155343062250130055607
Structural Cerebral Correlates of Perplexity: Exploring a Linguistic Marker in Cognitive Aging
Wang, X., Herold, C. J., Frankenberg, C., Ablimit, A., Schultz, T., Kong, L., & Schröder, J. (2025) · PsyCh Journal · doi:10.1002/pchj.70010
“Given the conceptualization of AD as a progressive neurodegenerative disorder that begins decades before the clinical manifestation (Lloret et al. 2019; Schröder et al. 2004), the identification of preceding cognitive markers is of special interest.”
Targeting Dementia: An Introduction
Hillman, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-85720-1_1
Understanding Sjögren's syndrome as a systemic autoimmune disorder
Chery, G. (2022) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/2wdp-zs5h · Cited by 2
fMRI in Neurodegenerative Diseases: From Scientific Insights to Clinical Applications
Dickerson, B. C., Canu, E., Tripodi, C., Agosta, F., & Filippi, M. (2025) · Neuromethods · doi:10.1007/978-1-0716-4438-6_24
Hakhu, S., Schaefer, S. Y., Beeman, S. C., & Initiative, A. D. N. (2025) · SSRN Electronic Journal · doi:10.1101/2025.07.23.25332087 · Cited by 1
“Our study expands on previous studies that demonstrate the association between amyloid deposition and neurite degradation in AD [40] by now demonstrating that amyloid deposition is associated with microstructural changes detected through diffusion magnetic resonance imaging (dMRI) that likely…”
Wilcockson, T. D. W., Pattison, M., & Begde, A. (2025) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/smuxv_v2
De saines habitudes de vie peuvent prévenir jusqu’à 40 % des cas de démence
Tremblay, S. A. (2023) · The Conversation · doi:10.64628/aap.9v3enkrjt
Mudanças no estilo de vida podem prevenir mais de 40% dos casos de Alzheimer e outras demências
Tremblay, S. A. (2023) · The Conversation · doi:10.64628/ade.rtxe4eukh
Pathological cognitive decline in the elderly participants of the Vogel Study
Ettlinger, S. (2023) · Online Publication Service of Würzburg University (Würzburg University) · doi:10.25972/opus-26558
Forn Villanova, M. L. (2024) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Barrios, L. C. (2023) · Repositorio Institucional de la Universidad de Málaga (University of Málaga)
Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases
Tremblay, S. (2023) · The Conversation · doi:10.64628/aam.c49x3agnt
Santos Ortega, Á. (2025) · Repositorio Institucional de la Universidad de Málaga (University of Málaga)
A new look at blood biomarkers in Alzheimer’s patients
Bogolepova, A. N., Коваленко, Е. А., Gileva, E. A., Makhnovich, E. V., Gasilova, A. D., & Skvortsov, D. I. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20251251217
Detecting Dementia Using Lexical Analysis: Terry Pratchett’s Discworld Tells a More Personal Story
Pattison, M., Begde, A., & Wilcockson, T. D. W. (2026) · Brain Sciences · doi:10.3390/brainsci16010094
“However, Alzheimer’s pathology likely begins many years and perhaps decades before the onset of symptoms [4].”
The evolution of disease criteria in multiple sclerosis: underlying motives and broader implications
Leeuwenberg, K. E., van der Molen, L. H., Boenink, M., & Richard, E. (2026) · BMC Neurology · doi:10.1186/s12883-026-04641-x
“…who would have previously been considered healthy, and show how the emphasis on biomarkers has shifted our understanding of MS. Similar changes in disease criteria have occurred in other neurological diseases, including Alzheimer’s Disease and more recently also Parkinson’s Disease [5, 6].”
A Cautionary Tale of Self-Supervised Learning for Imaging Biomarkers: Alzheimer's Disease Case StudyPreprint
Reynolds, M. J., Srinivasan, C., Cherupally, V. K., Leone, M. J., Yu, K., Sun, L., Chaudhary, T., Pfenning, A. R., & Batmanghelich, K. N. (2026) · arXiv (Cornell University) · doi:10.48550/arxiv.2601.16467
“Alzheimer’s disease (AD) neuropathology is a process that begins years, even decades, before the onset of clinical symptoms such as confusion and memory impairment [1].”
APOE, Biomarkers, and Proteogenomics in Alzheimer’s Disease
Pereira, J. D., Tosatti, J. A. G., & Gomes, K. B. (2026) · Springer eBooks · doi:10.1007/978-3-031-52641-1_66-1
Cannabinoids as modulators for Alzheimer’s disease: a role for microglia?
Vecchiarelli, H. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27340-7.00002-4
Aivo-selkäydinnesteen ja veren merkkiaineet yhä tärkeämpiä Alzheimer-diagnostiikassa
Lehmuskoski, R., & Martikainen, M. H. (2026) · UTUPub (University of Turku)
Li, X., Zeng, X., Li, J., Zheng, Y., Tian, S., Wang, Z., Ma, C., Lin, Y., Lin, G., Zeng, Y., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261431797
Abdelouahab, O. B. (2021) · theses.fr (ABES) · doi:10.70675/97f4885fz3f5cz4234zb8e2ze3fa7c4e3d41
APOE, Biomarkers, and Proteogenomics in Alzheimer’s Disease
Pereira, J. D., Tosatti, J. A. G., & Gomes, K. B. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_66
Barlis, K., Horner, M. D., Mintzer, J. E., Back, S. E., Lawson, A., Crull, J., Yaffe, K., Absher, J., Brawman‐Mintzer, O., & Joseph, J. E. (2026) · Journal of Head Trauma Rehabilitation · doi:10.1097/htr.0000000000001179
Pinnawala, S., Hartanto, A., Jairamani, M., Simpson, I., & Wijeratne, P. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.07.730710
Heterochronic bone marrow transplantation alters behavioral measures in middle-aged mice
Nakazawa, S., Yokogawa, K., Ogawa, R., Hizawa, K., Sashida, G., Sasaki, T., & Arimura, N. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00296-z
“By the time memory deficits or impaired executive functions become apparent, irreversible changes—such as marked hippocampal atrophy and neuronal loss—have often already occurred [8, 9].”
Application of artificial intelligence in early diagnosis of alpha-synucleinopathies
Ghosh, N., & Sinha, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43934-6.00020-1
A New Look at Blood Biomarkers in Patients with Alzheimer’s Disease
Bogolepova, A. N., Коваленко, Е. А., Gileva, E. A., Makhnovich, E. V., Gasilova, A. D., & Skvortsov, D. I. (2026) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-026-02018-8
“A β peptides vary in size from 39 to 43 amino acids; A β 40, which is less prone to aggregation, is the most abundant peptide variant in CSF (approximately 60% of total A β ) as compared with A β 42, which directly promotes the formation of toxic oligomers [3].”
Morris, S. A. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261472068
“…late-onset (LOAD), and rare autosomal dominantly inherited familial (fAD) variants, usually early-onset (EOAD); prion-like amyloid-β (A β ) 42 and hyperphosphorylated tau (ptau) oligomers; 1 a decades-long clinical latency, 2,3 and a focal anatomic origin 4 with a speci fi c pattern of spread.”
Hernández, D. L. P., Sánchez, Á. A. L., & Juárez, R. G. (2026) · Casos y Revisiones de Salud · doi:10.22201/fesz.26831422e.2026.8.1.6
Mittal, A., Bhadana, P., Pathak, A., Paramanick, D., Gadewar, M. M., & Chaudhary, H. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100707
Alzheimer's Disease Epidemiology: Modifiable Risk Factors and Prevention
Negi, D., Singh, A. K., Kulyal, H., Rawat, S., & Negi, P. (2025) · Journal of Neonatal Surgery
Internship Report and Monograph entitled “Alzheimer's Disease in Individuals with Down Syndrome”.
Rodrigues, B. S. A. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Amado, A. C. G. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Malattia di Alzheimer: evoluzione approcci terapeutici investigstivi negli ultimi trent’anni
GIORGI, M. (2026) · Electronic Theses and Dissertations Repository (University of Pisa)
Magnusson, A., Meehan, A. D., Palm, E. C., Fresnais, D., Fure, B., Bejerot, S., Sayardoust, S., Demirel, I., & Humble, M. B. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261504327
Hu, X., Liu, C., Wang, K., Zhao, L., Qiu, Y., Chen, H., Hu, J., & Xu, J. (2022) · doi:10.3389/fchem.2022.842208.s001
Li, H., Wei, M., Ye, T., Liu, Y., Qi, D., & Cheng, X. (2022) · doi:10.3389/fneur.2022.901179.s003
Metadata
- Authors
- Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P.
- Affiliations
- Universitat de València (ES)
- Department of Clinic Neurophysiology. University Clinic Hospital of Valencia, Avda. Blasco Ibanez, 19, 46010 Valencia, Spain
- Department of Human Anatomy and Embriology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain
- Hospital Clínico Universitario de Valencia (ES)
- Corresponding author
- Lloret, Ana
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-11-06
- Volume
- 20
- Issue
- 22
- Pages
- 5536
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6888399
- OpenAlex
- W2985526400
- Cited by
- 131
- References
- 117
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 24 · 2023: 21 · 2022: 22 · 2021: 19 · 2020: 2
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
- Funders
- Ministerio de Economía, Industria y Competitividad, Gobierno de España (SAF2016-75508-R)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, disease onset, biomarkers, preclinical Alzheimer's disease, mild cognitive impairment, dementia, amyloid-beta, tau protein, glucose hypometabolism, brain atrophy, NIA-AA criteria, disease continuum, early diagnosis
- MeSH terms
- Alzheimer Disease, Humans, Risk Factors, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.